The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet.
Dengue is a mosquito-borne disease that infects around 390 million people each year, of whom about 96 million suffer from symptomatic infection. WHO estimates that the global burden of dengue has risen 30-fold over the past 50 years, with over half of the world’s population at risk of the disease.
There is no licensed vaccine available to treat or prevent dengue fever, and efforts to develop one have been complicated by the fact that dengue is caused by four distinct dengue viruses, and a vaccine must target all four serotypes (DENV 1–4).
This phase 3 trial took place in dengue-endemic areas across five countries in Asia, a region that accounts for over 70% of the global dengue burden. The study involved 10 275 healthy children aged 2 to 14 years who were randomly assigned to receive three injections of the CYD-TDV vaccine (6851) or a placebo (3424) at 0, 6, and 12 months, and followed for up to 2 years.
The researchers recorded 250 dengue cases more than 28 days after the third injection—117 in the vaccine group and 133 in the placebo group, demonstrating an overall protective efficacy of 56.5%.
The vaccine also showed 88.5% efficacy after 3 doses against severe disease (dengue haemorrhagic fever) which leads to hospitalisation for over half a million people (mostly children) every year, and 67% against dengue-associated hospitalisation.
Read more . . .
The Latest on: Dengue vaccine
[google_news title=”” keyword=”Dengue vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Dengue vaccine
- A vaccine against dengue in times of crisis: How, where and when?on April 26, 2024 at 8:49 pm
The drug Qdenga, which has begun to be distributed massively in Brazil, could be a useful tool against a disease on the rise in Latin America ...
- Climate change need not mean more dengue cases if cities are built better: Expertson April 26, 2024 at 3:00 am
When warmer temperatures put stress on the agriculture sector, for instance, more people may move to cities, which is exactly where the Aedes mosquito and the dengue virus thrive, with the virus ...
- Japanese vaccine against dengue approved for use in Argentinaon April 25, 2024 at 5:00 pm
The vaccine, called TAK-003, is based on dengue virus 2, to which DNA from the other three serotypes is added to protect against any of the four types of dengue, it was explained.
- Lessons for dengue vaccines from a human challenge studyon April 25, 2024 at 4:05 pm
Dengue is an acute mosquito-borne illness that is caused by four different dengue viruses (serotypes 1–4). More than half the world's population lives at risk of dengue. Among the different approaches ...
- Babies of dengue-infected pregnant women shown to be at high risk for poor health in first years of lifeon April 25, 2024 at 9:23 am
The newborns of women who had even mild dengue fever during pregnancy had a 67% and 133% greater risk of being classified as very and extremely low birth weight, respectively.
- Dengue fever is surging in Latin Americaon April 25, 2024 at 6:57 am
Brasilía is a hotspot, but dengue is spiking across Brazil and Latin America. In 2023 the region hosted 80% of the world’s confirmed dengue cases, according to the UN ’s World Health Organisation.
- Bali urges foreign tourists to get dengue fever vaccines amid increasing caseson April 22, 2024 at 9:30 pm
Bali advises tourists to get vaccinated against dengue fever for health. Bali Health Agency emphasizes importance for residents and visitors. Proactive measures taken amid rising cases. Indian ...
- Dengue cases top 5.2 million in the Americas as outbreak passes yearly record, PAHO sayson April 19, 2024 at 3:40 pm
Dengue cases are surging in the Americas, with cases reported topping 5.2 million as of this week, surpassing a yearly record set in 2023, according to the Pan American Health Organization (PAHO).
- DNA vaccine against Zika performs well in tests on miceon April 18, 2024 at 9:47 am
In Brazil, researchers at the University of São Paulo (USP) and the Pernambuco division of Oswaldo Cruz Foundation (FIOCRUZ) are developing a Zika vaccine. The formulation was tested on mice and found ...
- Dengue cases surge by nearly 50% in Americas amid 'emergency situation', UN agency sayson April 18, 2024 at 9:44 am
Dengue cases have created an "emergency situation" in the Americas, although cases in hotspots Argentina and Brazil appear to have stabilized, the head of the Pan American Health Organization (PAHO) ...
via Bing News
